Evaluating blood clotting parameters in cancer patients undergoing surgery
Use of Viscoelastic Assays Beyond Coagulation: Pre- and Post-operative TEG
This study is testing how blood clotting measurements in cancer patients before and after surgery can help predict complications and outcomes for those with different types of adenocarcinoma.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | University of Colorado, Denver Academic / other |
| Locations | 1 site (Aurora, Colorado) |
| Trial ID | NCT05517811 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the relationship between thromboelastography (TEG) parameters and disease burden in patients diagnosed with various types of adenocarcinoma, including liver, esophageal, colorectal, and lung cancers. It will compare pre-operative TEG indices with routine coagulation parameters to predict post-operative complications such as thrombosis and hemorrhage. Additionally, the study will investigate whether changes in TEG parameters after surgery can indicate successful cancer resection and predict recurrence and overall survival. Proteomic analyses will also be conducted on tumor samples to explore correlations between histology and TEG abnormalities.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a new diagnosis of hepatopancreaticobiliary, esophageal, colorectal, or lung adenocarcinoma.
Not a fit: Patients under 18, those unable to provide informed consent, pregnant women, and individuals requiring urgent surgical intervention may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide new biomarkers for assessing cancer severity and predicting post-operative outcomes in patients with adenocarcinoma.
How similar studies have performed: While the approach of using TEG parameters in cancer patients is innovative, similar studies have shown promise in correlating coagulation profiles with cancer outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * new diagnosis by the providing physician of hepatopancreaticobiliary, esophageal, colorectal or lung adenocarcinoma will be eligible for enrollment in the study * 18 Years and older Exclusion Criteria: * Under 18 years old * prisoners * those unable to provide informed consent * pregnant women * and those undergoing emergent or urgent operative intervention at the time of diagnosis
Where this trial is running
Aurora, Colorado
- University of Colorado Denver — Aurora, Colorado, United States (Recruiting)
Study contacts
- Principal investigator: Ana Gleisner, MD — University of Colorado, Denver
- Study coordinator: Tracey MacDermott, BA BS CCRC
- Email: tracey.macdermott@cuanschutz.edu
- Phone: 303-724-2757
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.